中文名 | 2-氨基-5-[(5-硝基-2-噻唑基)硫代]-1,3,4-噻二唑 |
英文名 | 5-[(5-Nitro-2-thiazolyl)thio]-1,3,4thiadiazol-2-amine |
别名 | 化合物SU3327 5-((5-硝基噻唑-2-基)硫基)-1,3,4-噻二唑-2-胺 2-氨基-5-[(5-硝基-2-噻唑基)硫代]-1,3,4-噻二唑 |
英文别名 | SU 3327 Halicin 5-[(5-Nitro-2-thiazolyl)thio]-1,3,4thiadiazol-2-amine 2-Amino-5-[(5-nitro-2-thiazolyl)thio]-1,3,4-thiadiazole 1,3,4-Thiadiazol-2-amine, 5-[(5-nitro-2-thiazolyl)thio]- 5-[(5-nitro-1,3-thiazol-2-yl)sulfanyl]-1,3,4-thiadiazol-2-amine |
CAS | 40045-50-9 |
化学式 | C5H3N5O2S3 |
分子量 | 261.3 |
密度 | 1.88±0.1 g/cm3(Predicted) |
熔点 | 160 °C(dec.) |
沸点 | 549.8±42.0 °C(Predicted) |
酸度系数 | 0.65±0.10(Predicted) |
存储条件 | Store at RT |
外观 | 淡黄色固体 |
体外研究 | SU3327 (compound 9) is able to inhibit TNF-α stimulated phosphorylation of c-Jun in HeLa cells (EC 50 = 6.23 μM). SU3327 (25 nM) pretreatment of human-derived cerebral microvascular endothelial cells (hCMEC/D3) effectively reduces LPS-induced polymorphonuclear leukocytes (PMN) rolling/adhesion to hCMEC/D3, prevents activation of AP-1, and significantly reduces expression of VCAM-1. |
体内研究 | SU3327 (Compound 9; 25 mg/kg; intraperitoneal injection; male BKS.Cg-+Lepr db /+Lepr db /OlaHsd db/db mice) treatment possesses the ability to restore insulin sensitivity in mice models of diabetes. SU3327 (Compound 9) has favorable microsomal and plasma stability (T 1/2 = 27 min). Animal Model: Male BKS.Cg-+Lepr db /+Lepr db /OlaHsd db/db mice (11-week-old ) injected with insulin Dosage: 25 mg/kg Administration: Intraperitoneal injection Result: Resulted in a statistically significant reduction in blood glucose levels. |